- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07950215
A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia
A Phase 3, Multi-center, Randomized, Open-Label, Active-Controlled, Efficacy and Safety Study of AND017 to Treat Anemia in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
This is a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of AND017 in non-dialysis-dependent (NDD)-CKD patients with anemia compared with the active control, erythropoietin stimulating agents (ESA).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Yusha Zhu, M.D., Ph.D.
- Numéro de téléphone: 646-725-2552
- E-mail: yusha.zhu@kindpharma.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Capable of providing signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
-
Body weight from 45-140 kg inclusive.
-
A diagnosis of CKD confirmed at screening, CKD stage 3, 4, or 5 defined by eGFR <60 mL/min/1.73 m2.
-
Prior ESA use and Hb levels:
- ESA-naïve: Defined as no use of any ESA treatment for at least 12 weeks before randomization; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be ≥7.5 g/dL and <10.0 g/dL.
- ESA-treated: Defined as having received an approved ESA, administered intravenously or subcutaneously, for at least 6 weeks prior to randomization, with no change in ESA product and no treatment interruption exceeding two consecutive weeks; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be 9.0-11.0 g/dL inclusive.
-
TSAT ≥20% or ferritin ≥100 ng/mL at screening test.
-
Serum folate and vitamin B12 ≥ lower limit normal (LLN) at screening test
-
Total bilirubin ≤1.5× upper limit normal (ULN). For Gilbert's Syndrom, <3×ULN.
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN
-
No evidence of other causes of anemia caused by a pathologic process in the hematopoietic system, including intra- or extravascular hemolysis, or myelodysplasia
-
No other primary cause for anemia other than CKD.
Exclusion Criteria:
- Concurrent retinal neovascular lesions requiring treatment including proliferative diabetic retinopathy, exudative age-related macular degeneration, retinal vein occlusion, macular edema, etc.
- Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis or concurrent autoimmune disease with inflammatory symptoms.
- History of gastric/intestinal resection considered to affect the absorption of drugs in the gastrointestinal tract or concurrent symptomatic gastroparesis despite being on treatment.
- Clinically significant bleeding within 4 weeks of first dose; bleeding diathesis or risk of bleeding that has not been medically or surgically corrected at least 4 weeks prior to first dose of study drug.
- History or concurrent hemosiderosis, hemochromatosis or hyper-coagulable condition.
- Uncontrolled hypertension, defined as patients with hypertension having more than one of three systolic blood pressure (SBP) >180 mmHg, or diastolic blood pressure (DBP) >110 mmHg during the screening period.
- History of stroke, transient ischemic attack, myocardial infarction, thromboembolic event , pulmonary embolism, or lung infarction within 24 weeks before the screening assessment.
- Participants with a history of significant liver disease or active liver disease.
- History of a seizure disorder or any occurrence of seizures in the past.
- History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
- History of a seizure disorder or any occurrence of seizures in the past.
- History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
- Having undergone blood transfusion and/or a surgical procedure that caused major blood loss within 8 weeks before the screening assessment
- Participants that have major surgery planned during the study period.
- Any prior functioning organ transplant or a scheduled organ transplantation, or anephric.
- Serum albumin (ALB) < 2.5 g/dL at screening test.
- Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody at the screening assessment, or positive for human immunodeficiency virus in a past test.
- Having received any investigational drug in an interventional clinical trial within 5 weeks before the randomization.
- A known history of allergic reactions to ESA treatment.
- History of serious drug allergies.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: AND017
|
AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients |
|
Comparateur actif: ESA
|
ESA injection and dose based on package insert and local practice |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The mean Hb levels averaged over Week 25-29
Délai: Week 25 to Week 29
|
Evaluate the efficacy of AND017 for treatment of anemia in patients with NDD-CKD |
Week 25 to Week 29
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of responders over the main treatment period
Délai: Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
defined as patients who meet either of the following criteria: For patients with baseline Hb 9.0 g/dL: mean Hb ≥ 10.0 g/dL during Weeks 25-29 and a change from baseline ≥ -1.0 g/dL during Weeks 25-29; For patients with baseline Hb < 9.0 g/dL: an increase in Hb from baseline ≥ 1.0 g/dL during Weeks 3-29 |
Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
|
Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29
Délai: Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29 |
Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
|
The percentage of response visits over the entire study treatment
Délai: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Response visit is defined as after first reaching ≥ 10.0 g/dL, Hb maintained within the target range of 10.0-11.0 g/dL |
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
The cumulative incidence of Hb non-response over Weeks 5-29
Délai: Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
Non-response is defined as Hb < 10.0 g/dL and an increase from baseline < 1.0 g/dL |
Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
|
Change from baseline in serum iron over the entire treatment period
Délai: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in ferritin over the entire treatment period
Délai: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in transferrin over the entire treatment period
Délai: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in transferrin saturation over the entire treatment period
Délai: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in total iron binding capacity over the entire treatment period
Délai: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
The percentage of patients received intravenous iron treatment during the entire study
Délai: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
During the entire treatment period, the mean weekly dose of intravenous iron treatment (mg)
Délai: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
During the entire treatment period, the time to first initiation of intravenous iron treatment (Day)
Délai: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in total cholesterol over the entire treatment period
Délai: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in low density lipoprotein over the entire treatment period
Délai: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in high density lipoprotein over the entire treatment period
Délai: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in triglycerides over the entire treatment period
Délai: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AND017-US-303
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .